Quantum BioPharma (QNTM, Financial) has successfully completed the dosing phase in a 90-day oral toxicity and toxicokinetic study for its drug candidate, Lucid-21-302, aimed at treating Multiple Sclerosis. These important studies have been conducted to gather crucial data necessary for submitting an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Quantum BioPharma Ltd (QNTM, Financial) is $169.00 with a high estimate of $169.00 and a low estimate of $169.00. The average target implies an upside of 1,762.26% from the current price of $9.08. More detailed estimate data can be found on the Quantum BioPharma Ltd (QNTM) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Quantum BioPharma Ltd's (QNTM, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
